HAM-A: Hamilton Anxiety Rating Scale
Clinician-administered scale measuring the severity of anxiety symptoms across psychic and somatic subscales. Criterion standard for clinical trials.
HAM-A Score Interpreter
Clinically significant but limited functional impact; monitor closely.
14 items, each scored 0–4. Total = sum of all items (0–56). Higher scores indicate greater severity.
| Total score | Interpretation |
|---|---|
| 24+ | Severe anxietySignificant impairment across multiple domains; warrants close clinical attention. |
| 15–23 | Moderate anxietyLikely functional impairment; treatment response monitoring recommended. |
| 8–14 | Mild anxietyClinically significant but limited functional impact; monitor closely. |
| 0–7 | Minimal / no anxietyScores ≤7 indicate no clinically significant anxiety. |
Hamilton M (1959); severity ranges per Matza LS et al., Int J Methods Psychiatr Res. 2010;19(4):223-32. Use with caution and validated clinical judgment. Educational reference only — not a diagnostic tool.
The HAM-A is the criterion-standard 14-item observer-rated scale for measuring anxiety symptom severity. Validated in 500+ clinical trials and the benchmark comparator for anxiety treatment research.
What is the HAM-A?
The HAM-A (Hamilton Anxiety Rating Scale) is a 14-item clinician-administered rating scale developed by Max Hamilton in 1959 to quantify anxiety symptom severity. It remains the most widely used observer-rated anxiety scale in pharmacological clinical trials and is considered the benchmark comparator for evaluating anxiolytic treatments.
Each of the 14 items represents a cluster of symptoms and is scored on a 5-point scale (0 = not present, 4 = very severe), yielding total scores from 0 to 56. The scale measures both psychic anxiety (mental and cognitive symptoms, items 1–6 and 14) and somatic anxiety (physical symptoms, items 7–13), making it uniquely valuable for distinguishing between these two anxiety dimensions in clinical research.
The HAM-A has been translated into 50+ languages and validated across generalized anxiety disorder (GAD), panic disorder, social anxiety, and mixed anxiety-depression presentations. A clinically significant change is typically defined as a ≥50% reduction in score or a final score below the threshold for moderate anxiety (≤14).
Clinician-Administered Tool
The HAM-A is designed for clinician administration. Each item requires clinical judgment based on both the patient's verbal report and direct behavioural observation during the interview. It is intended for use in educational, training, and outcome-tracking contexts by licensed clinicians.
Rate each symptom cluster based on the patient's report and your clinical observation over the past week. Score each item 0–4.
For trained clinician use. Scores require clinical context and professional judgment.
HAM-A Scoring & Severity Levels
Each item scored 0–4: 0 = not present, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe. Total score = sum of all 14 items (range 0–56).
The following severity bands were derived and validated by Matza et al. (2010) using MANOVA models against clinician CGI-S ratings and SF-36 functional status data in a GAD sample (n = 144):
| Total Score | Severity | Typical Functional Impact |
|---|---|---|
| 0–7 | None / minimal | No clinically significant anxiety |
| 8–14 | Mild | Limited functional impact; monitor |
| 15–23 | Moderate | Likely functional impairment |
| ≥24 | Severe | Significant impairment; active treatment indicated |
A treatment response threshold of ≥50% reduction from baseline is widely used in pharmacological trials. Matza et al. note these cutoffs should be applied with caution and validated in larger samples.
Psychic Anxiety Subscale
Items 1–6 and 14 (anxious mood, tension, fears, insomnia, intellectual, depressed mood, behavior at interview). Max = 28.
Reflects cognitive, emotional, and behavioural manifestations of anxiety.
Somatic Anxiety Subscale
Items 7–13 (muscular, sensory, cardiovascular, respiratory, GI, GU, autonomic). Max = 28.
Reflects physical and autonomic symptoms of anxiety. Particularly useful in differentiating anxiety from depression.
HAM-A Items & Scoring Anchors
Each item covers a symptom cluster. Score based on the most prominent symptom within each cluster over the past week.
| # | Item | Subscale | Key symptom clusters |
|---|---|---|---|
| 1 | Anxious mood | Psychic | Worry, anticipation of the worst, fearful anticipation, irritability |
| 2 | Tension | Psychic | Feelings of tension, fatigue, startle response, inability to relax, tearfulness, trembling |
| 3 | Fears | Psychic | Fear of dark, strangers, being left alone, animals, traffic, crowds |
| 4 | Insomnia | Psychic | Difficulty falling asleep, broken sleep, unsatisfying sleep, dreams, nightmares |
| 5 | Intellectual (cognitive) | Psychic | Difficulty concentrating, poor memory |
| 6 | Depressed mood | Psychic | Loss of interest, lack of pleasure in hobbies, depression, early waking, diurnal mood swing |
| 7 | Somatic (muscular) | Somatic | Muscular pains, aches, stiffness, twitching, grinding of teeth, unsteady voice, increased muscular tone |
| 8 | Somatic (sensory) | Somatic | Tinnitus, blurring of vision, hot/cold flushes, feelings of weakness, prickling sensation |
| 9 | Cardiovascular symptoms | Somatic | Tachycardia, palpitations, pain in chest, throbbing of vessels, faintness, skipped beat |
| 10 | Respiratory symptoms | Somatic | Pressure or constriction in chest, choking feelings, sighing, dyspnea |
| 11 | Gastrointestinal symptoms | Somatic | Difficulty swallowing, flatulence, dyspepsia, borborygmi, nausea, vomiting, looseness of bowels, loss of weight |
| 12 | Genitourinary symptoms | Somatic | Frequency of micturition, urgency, amenorrhea, menorrhagia, frigidity, premature ejaculation |
| 13 | Autonomic symptoms | Somatic | Dry mouth, flushing, pallor, sweating, giddiness, tension headache |
| 14 | Behaviour at interview | Psychic | Fidgeting, restlessness, tremor, furrowed brow, strained face, sighing, rapid breathing |
Clinical Use & Psychometrics
Reliability
The HAM-A has acceptable inter-rater reliability across studies, with intraclass correlation coefficients (ICC) generally reported in the moderate-to-high range. Internal consistency (Cronbach's α) varies across populations, reflecting the scale's heterogeneous item content spanning both psychic and somatic symptom clusters. A 2023 expert working group (Rabinowitz et al.) analyzed 40,349 HAM-A administrations across 15 clinical trials and found that approximately 35% contained at least one scoring inconsistency flag, highlighting the importance of rater training and structured administration guides to maintain measurement fidelity.
The two-factor structure — psychic and somatic subscales — has been replicated across multiple populations and samples (Marks et al., 2022), though the subscales perform less consistently when used independently than the total score does. There is moderate overlap between HAM-A total scores and depression severity measures such as the HAM-D, reflecting the common co-occurrence of anxiety and depressive symptoms.
Responsiveness
A ≥50% reduction in total score from baseline is the most commonly used responder threshold in pharmacological trials. The HAM-A has been a primary or co-primary efficacy endpoint in clinical trials of SSRIs, SNRIs, and benzodiazepines since the 1960s, providing a large normative database for cross-study comparisons.
HAM-A vs GAD-7: Choosing the Right Tool
The HAM-A and GAD-7 serve complementary rather than competing roles in clinical practice. Choosing between them depends on the clinical context, available time, and the specific information needed.
| Feature | HAM-A | GAD-7 |
|---|---|---|
| Format | Clinician-administered interview | Patient self-report |
| Items | 14 | 7 |
| Completion time | 10–15 minutes (clinician) | 2–3 minutes (patient) |
| Subscales | Psychic anxiety + somatic anxiety | None (total score only) |
| Score range | 0–56 | 0–21 |
| Primary use | Clinical research endpoint; detailed severity tracking | Screening; routine outcome monitoring |
| Sensitivity for GAD | High (clinician judgment) | 89% at optimal cut-point (Spitzer et al., 2006) |
| Requires clinician time | Yes | No |
| Cost | Free (public domain) | Free (public domain) |
The GAD-7 is generally the preferred choice for population-level screening, routine outcome monitoring in primary care, and high-volume settings where clinician-administered interviews are not practical. It identifies probable GAD cases efficiently and has been validated across large primary care samples (Spitzer et al., 2006).
The HAM-A is the better choice when clinician judgment is necessary to separate somatic symptoms of anxiety from those with a medical origin, when psychic versus somatic anxiety profiles are clinically meaningful (e.g., differentiating medication response patterns), or when a rigorous, widely benchmarked outcome measure is required for research. Its long track record in pharmacological trials means HAM-A scores carry normative context that the GAD-7 cannot yet match for treatment effect comparisons.
In measurement-based care settings, both instruments can be used together: the GAD-7 at each visit for rapid tracking, with the HAM-A reserved for baseline assessment, complex presentations, or clinical trial protocols.
Automate HAM-A in Your Practice
HiBoop enables structured HAM-A administration, automated scoring, longitudinal tracking, and outcome reporting, for any clinic size.
Related Assessments
GAD-7 — 7-item self-report anxiety scale. Faster screening alternative to HAM-A for routine outcome monitoring and population-level screening.
HAM-D (Hamilton Depression Rating Scale) — Clinician-administered depression severity scale. Often co-administered with HAM-A in mixed anxiety-depression presentations to profile symptom dimensions separately.
DASS-21 (Depression Anxiety Stress Scales) — 21-item self-report scale measuring depression, anxiety, and stress. Complements HAM-A for broader symptom profiling in research contexts.
Frequently Asked Questions
What is the HAM-A?
The Hamilton Anxiety Rating Scale (HAM-A) is a 14-item clinician-administered scale developed by Max Hamilton in 1959 to quantify anxiety symptom severity. It remains the most widely used observer-rated anxiety scale in pharmacological clinical trials and is considered the benchmark for evaluating anxiolytic treatments.
How are HAM-A scores interpreted?
HAM-A scores range from 0 to 56. A score of 7 or below indicates no clinically significant anxiety; 8–14 mild anxiety; 15–23 moderate anxiety with likely functional impairment; and 24 or above indicates severe anxiety. These ranges were validated by Matza et al. (2010) against clinician CGI-S ratings and functional status measures. A clinically significant treatment response is typically defined as a 50 per cent or greater reduction in score.
How does the HAM-A differ from self-report scales like the GAD-7?
The HAM-A is administered by a trained clinician through a structured interview, while the GAD-7 is completed by the patient without a clinician. The HAM-A captures both observable signs and subjective reports and provides separate subscale scores for psychic anxiety and somatic anxiety. The GAD-7 is faster and better suited for population screening and routine monitoring. The HAM-A is preferred when somatic versus psychic anxiety distinction matters clinically or when a rigorous endpoint is needed for research.
Why is the HAM-A used in clinical trials?
The HAM-A has been the primary or secondary efficacy endpoint in hundreds of clinical trials evaluating anxiolytic medications, including SSRIs, SNRIs, and benzodiazepines. Its clinician-rated format reduces response bias, and its psychic and somatic subscales allow for differentiation of anxiety symptom profiles. It has been used since the 1960s, giving it a large normative database for cross-study comparisons.
How does the HAM-A compare to the GAD-7 for routine clinical use?
For routine clinical use and population-level screening, the GAD-7 is generally preferred because it takes 2 to 3 minutes, requires no clinician time to administer, and is freely available. The HAM-A takes 10 to 15 minutes of clinician time and is better suited for detailed clinical assessment, treatment monitoring in complex cases, and research contexts where subscale data and inter-rater reliability are important.
Does HiBoop support the HAM-A?
Yes. HiBoop supports HAM-A administration with an interactive item-by-item scoring interface, automatic subscale calculation for psychic and somatic anxiety, severity classification, and longitudinal tracking across visits.
References
- 1.Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55.View source
- 2.Matza LS, Morlock R, Sexton C, et al. Identifying HAM-A cutoffs for mild, moderate, and severe generalized anxiety disorder. Int J Methods Psychiatr Res. 2010;19(4):223-32.View source
- 3.Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092-7.View source
- 4.Rabinowitz J, Williams JBW, Hefting N, et al. Consistency checks to improve measurement with the Hamilton Rating Scale for Anxiety (HAM-A). J Affect Disord. 2023;325:429-436.View source
Bill this assessment
The HAM-A: Hamilton Anxiety Rating Scale qualifies for reimbursement under these CPT codes (US).
Last reviewed: Jun 3, 2026
Related Assessments
Explore complementary clinical tools and screeners